Er Shen Wan extract alleviates polyuria and regulates AQP 2 and AVPR 2 in a rat model of spleen-kidney Yang deficiency–induced diarrhea
Autor: | Mingyang Gao, Li Yidan, Da Chen, Kaixuan Zheng, Yun Li, Rui Xiong, Yumei Lian, Hu Changjiang, Zhang Tingting |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Diarrhea
Male 0301 basic medicine Receptors Vasopressin Vasopressin medicine.medical_specialty Urinary system Extract RM1-950 Kidney Rats Sprague-Dawley Random Allocation 03 medical and health sciences chemistry.chemical_compound Er Shen Wan 0302 clinical medicine Polyuria Internal medicine medicine Animals Renal water absorption Pharmacology AQP 2 Aquaporin 2 Aldosterone business.industry Urination disorder General Medicine Rats Disease Models Animal AVPR 2 Yang Deficiency 030104 developmental biology Endocrinology medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis Therapeutics. Pharmacology medicine.symptom business Spleen Drugs Chinese Herbal |
Zdroj: | Biomedicine & Pharmacotherapy, Vol 110, Iss, Pp 302-311 (2019) |
ISSN: | 0753-3322 |
Popis: | Ethnopharmacological relevance Er Shen Wan (ESW), has been empirically used for treating spleen-kidney Yang deficiency (SKYD) syndrome in Traditional Chinese medicine (TCM) for centuries and shows a variety of activities. The medicinal formula is a mixture of two component herbs, Psoraleae Fructus (PF, Bu-Gu-Zhi in Chinese) and Myristicae Semen (MS, Rou-Dou-Kou in Chinese). The current study was designed to evaluate ESWP antidiuretic treatment of polyuria and to explore potential mechanisms of renal water metabolism in the rat model of SKYD-induced diarrhea. Materials and methods An animal model of ‘SKYD–induced diarrhea syndrome’ has been established to evaluate the therapeutic effect and action mechanism according to the clinical syndrome and symptoms. The optimal dose (3.5 g/kg) of ESWP was given to rats by gavage for two weeks. Urinary volumes after 24 h were recorded. After the end of the trial, macroscopic morphological and histological examination of the kidney were conducted. Serum levels of Arginine vasopressin (AVP) and aldosterone (ALD) were also measured. Additionally, quantitative real-time RT-PCR (RT-qPCR) and immunohistochemistry (IHC) analyses were performed to clarify the regulation of aquaporin 2 (AQP 2) and arginine vasopressin type 2 receptor (AVPR 2) in the kidney at the gene and tissue expression levels respectively. Results After the administration of ESWP, urinary output volume after 24 h was found to be significantly decreased in rats. Elevated plasma levels of AVP and ALD were detected. Histological kidney damage appeared to be impeded, and histological disease scores were reduced. In addition, the expression levels of AQP 2 and AVPR 2 were significantly increased. Conclusion This study suggests that ESWP may elicit significant effects on the treatment of polyuria. Potential mechanisms at least partially involve hormone regulation, and alleviating renal pathological damage. Simultaneously, ESWP may alter renal water absorption by increasing AQP 2 and AVPR 2 expression levels. Thus, the in vivo experimental evidence indicates that ESWP has a therapeutic effect on the SKYD syndrome, which is consistent with its traditional usage. |
Databáze: | OpenAIRE |
Externí odkaz: |